Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 5-13, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blake, J.
Right arrow Articles by Orrego, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blake, J.
Right arrow Articles by Orrego, H.

Clinical Chemistry, Vol 37, 5-13, Copyright © 1991 by American Association for Clinical Chemistry

Monitoring treatment of alcoholic liver disease: evaluation of various severity indices

J Blake and H Orrego
Addiction Research Foundation, Clinical Institute, Toronto, Ontario, Canada.

Monitoring the effectiveness of treatment sfor alcoholic liver disease involves the use of variables that have prognostic significance and are unaffected by the treatment in unspecific ways. Here we review the value of histological and functional variables for this purpose. We conclude that histological variables, although important in defining the characteristics of the sample, have several practical problems. The functional variables are most effective when used in combinations, e.g., in global indices such as the Combined Clinical and Laboratory Index, the Child-Turcotte-Pugh Index, or the Cox model. In situations involving mortality and dropouts, functional indices cannot be used to measure changes in severity; in such cases, mortality might be the only measure for assessing the effectiveness of a treatment. In clinical trials, it is essential to determine the risk of a Type II error, to monitor compliance and drinking, and to trace appropriately all the patients who were not compliant or who dropped out of the trial.


The following articles in journals at HighWire Press have cited this article:


Home page
 Alcohol AlcoholHome page
J. HIETALA, H. KOIVISTO, P. ANTTILA, and O. NIEMELA
COMPARISON OF THE COMBINED MARKER GGT-CDT AND THE CONVENTIONAL LABORATORY MARKERS OF ALCOHOL ABUSE IN HEAVY DRINKERS, MODERATE DRINKERS AND ABSTAINERS
Alcohol Alcohol., September 1, 2006; 41(5): 528 - 533.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
P. Anttila, K. Jarvi, J. Latvala, J. E. Blake, and O. Niemela
DIAGNOSTIC CHARACTERISTICS OF DIFFERENT CARBOHYDRATE-DEFICIENT TRANSFERRIN METHODS IN THE DETECTION OF PROBLEM DRINKING: EFFECTS OF LIVER DISEASE AND ALCOHOL CONSUMPTION
Alcohol Alcohol., September 1, 2003; 38(5): 415 - 420.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.